top of page

Boehringer Ingelheim Supports BioLabs First EU Location BioLabs Heidelberg with Founding Sponsorship

Ingelheim, Germany and Heidelberg, Germany, 17.08.2020 - Boehringer Ingelheim signs strategic sponsorship agreement with Biolabs Global to support the launch of BioLabs first European Location in Heidelberg. The agreement runs over three years with a potential extension for two additional years. BioRN, the leading non-profit membership network supporting the Life Science Cluster in the Rhine-Neckar region has been working with Biolabs over the past year to adapt the US start-up incubator model to the German research and biotech environment. The BioLabs Heidelberg site is expected to open for innovative life science start-up companies in 2021.

BioLabs Global is the premier life-sciences and biotech co-working company founded in 2010 and operates laboratories in key life science clusters, making it the most successful life-science incubator operator in the US. Boehringer Ingelheim embraces the power of partnership and diversity of minds across the life-science community to create more breakthrough therapies that change patients’ lives. The new sponsorship is part of Boehringer Ingelheim’s unique “Grass Roots” program aiming at connecting the company with entrepreneurs and facilitating information sharing and open dialog.

As an integral part of the sponsorship, Boehringer Ingelheim provides expertise and offers guidance to start-up companies at the Heidelberg site. Boehringer Ingelheim will also be offering ‘Golden Tickets” to the companies once per year during the term of the sponsorship. In partnership with BioLabs, Boehringer Ingelheim has already awarded numerous entrepreneurs with one year of free lab space through the BioLabs’ ‘Golden Ticket’ program.

Ioannis Sapountzis, Ph.D., Global Head of Business Development and Licensing at Boehringer Ingelheim said, “We are delighted to support BioLabs’ expansion into Europe and are looking forward to supporting the young innovative life science companies moving into BioLabs’ startup incubator. We have an excellent long-term relationship with BioLabs and BioRN and highly value their initiatives and programs which reflect and enable our commitment to foster emerging science to bring more medical breakthroughs to patients.”

“We are thrilled to have Boehringer Ingelheim as a sponsor of the site, their decision to support this project demonstrates the strong commitment to the outstanding scientists and entrepreneurs in the region. Their partnership with BioLabs will provide a significant boost to the biotech start-up ecosystem in the Rhine-Main-Neckar area.” said Julia Schaft, managing director at BioRN.

Johannes Fruehauf, founder of BioLabs said, “We are excited to partner again with Boehringer Ingelheim, building on years of successful partnership in the US, to expand our program to Europe. Boehringer Ingelheim has proven to be an excellent partner and mentor to many of our startups, and has already partnered with several companies out of our network. Together, we will build a strong center of entrepreneurship and medical innovation in Heidelberg to complement and build upon the excellent academic environment already present.”

This is a joint Press Release from Boehringer Ingelheim and BioRN.

Download here the Press Release in German.

About Boehringer Ingelheim

Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

More information about Boehringer Ingelheim can be found at or in our annual report:

About BioRN

BioRN is the science and industry cluster of the Rhine-Main-Neckar region around Heidelberg, one of Germany’s strongest biotech hubs. It is a non-profit network fostering health innovations and serving its members by creating a rich translational ecosystem as well as promoting, representing and connecting the regional innovation stakeholders. Our vision is to develop the region into a world-leading life science cluster attracting international investments and top global talent.

BioRN has more than 100 institutional members, including the top academic and research institutions, 8 global pharmaceutical companies, a large range of small and medium-sized enterprises bolstering the life science ecosystem as well as local government organizations and interest groups.

About BioLabs

BioLabs is a membership-based network of shared laboratory facilities located in key geographies with proven biotech innovation clusters. BioLabs offers beautifully designed coworking environments that pair fully equipped and supported lab, office, and event spaces with relevant programming and unparalleled access to capital and industry partners. These fertile, supportive ecosystems allow young companies to shift their focus from startup operations to experimentation and innovation so they can reach their scientific potential quickly and achieve business success. Companies can start with a single lab bench and scale-up as they grow. The expanding BioLabs and Affiliates US network of labs now comprises sites in Boston and Cambridge, Massachusetts; Durham, North Carolina; San Carlos, San Diego and San Francisco, California; New York City, and Princeton, New Jersey; and Philadelphia, Pennsylvania; and is developing additional domestic and international sites.

Media Contacts

Boehringer Ingelheim:

Dr. Reinhard Malin Head of Communications Innovation Unit Boehringer Ingelheim Corporate Center GmbH Media + PR P: 49 6132 77-90815

Linda Ruckel Associate Director, Media and Corporate Reputation

Boehringer Ingelheim U.S. Media + PR


Dr. Annalisa Zuccotti

BioRN Cluster Management GmbH

Communication & Events Lead

P: 49 6221 4305-113


bottom of page